Haemonetics (STU:HAZ) Piotroski F-Score: 6 (As of Jul. 01, 2026) — Near Median


STU:HAZ Haemonetics Corp STU:HAZ
25 GF Score
Price €65.50
GF Value €74.16
! 4 Warning Signs
View Full Analysis

What is Haemonetics Piotroski F-Score?

Haemonetics STU:HAZ 25 Piotroski F-Score is 6 as of Jul. 01, 2026, which is at its 10-year median of 6.00. GuruFocus rates STU:HAZ with a GF Score™ of 25/100 and a GF Value™ of €74.16. The stock has 4 warning signs investors should review. Among 806 Medical Devices & Instruments companies, Haemonetics ranks better than 81.14% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Haemonetics has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Haemonetics's Piotroski F-Score or its related term are showing as below:

STU:HAZ' s Piotroski F-Score Range Over the Past 10 Years
Min: 5   Med: 6   Max: 8
Current: 6

During the past 13 years, the highest Piotroski F-Score of Haemonetics was 8. The lowest was 5. And the median was 6.

Haemonetics  (STU:HAZ) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Haemonetics Piotroski F-Score Related Terms


Haemonetics Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Haemonetics's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haemonetics Piotroski F-Score Chart

Haemonetics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 8.00 6.00 7.00 6.00

Haemonetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 7.00 7.00 7.00 6.00

STU:HAZ vs ITGR, IRTC, ESTA: Piotroski F-Score Comparison

For the Medical Devices subindustry, Haemonetics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haemonetics Piotroski F-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Haemonetics's Piotroski F-Score falls into.


STU:HAZ
25GF Score
Haemonetics Corp STU:HAZ
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 29.505 + 32.959 + 38.208 + -17.427 = €83 Mil.
Cash Flow from Operations was 15.081 + 94.845 + 79.904 + 61.364 = €251 Mil.
Revenue was 278.649 + 278.872 + 289.478 + 299.594 = €1,147 Mil.
Gross Profit was 166.676 + 165.922 + 172.838 + 171.453 = €677 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(2267.127 + 2134.635 + 2080.717 + 2127.22 + 2072.475) / 5 = €2136.4348 Mil.
Total Assets at the begining of this year (Mar25) was €2,267 Mil.
Long-Term Debt & Capital Lease Obligation was €1,055 Mil.
Total Current Assets was €722 Mil.
Total Current Liabilities was €244 Mil.
Net Income was 35.649 + 30.482 + 35.807 + 53.632 = €156 Mil.

Revenue was 312.304 + 311.305 + 332.858 + 305.804 = €1,262 Mil.
Gross Profit was 162.504 + 168.881 + 184.837 + 178.571 = €695 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(2019.944 + 2360.568 + 2275.227 + 2417.363 + 2267.127) / 5 = €2268.0458 Mil.
Total Assets at the begining of last year (Mar24) was €2,020 Mil.
Long-Term Debt & Capital Lease Obligation was €852 Mil.
Total Current Assets was €865 Mil.
Total Current Liabilities was €535 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Haemonetics's current Net Income (TTM) was 83. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Haemonetics's current Cash Flow from Operations (TTM) was 251. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=83.245/2267.127
=0.03671828

ROA (Last Year)=Net Income/Total Assets (Mar24)
=155.57/2019.944
=0.07701699

Haemonetics's return on assets of this year was 0.03671828. Haemonetics's return on assets of last year was 0.07701699. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Haemonetics's current Net Income (TTM) was 83. Haemonetics's current Cash Flow from Operations (TTM) was 251. ==> 251 > 83 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=1054.924/2136.4348
=0.49377776

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=852.138/2268.0458
=0.37571464

Haemonetics's gearing of this year was 0.49377776. Haemonetics's gearing of last year was 0.37571464. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=722.17/244.448
=2.95428885

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=864.852/534.755
=1.61728642

Haemonetics's current ratio of this year was 2.95428885. Haemonetics's current ratio of last year was 1.61728642. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Haemonetics's number of shares in issue this year was 46.412. Haemonetics's number of shares in issue last year was 49.476. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=676.889/1146.593
=0.5903481

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=694.793/1262.271
=0.55043093

Haemonetics's gross margin of this year was 0.5903481. Haemonetics's gross margin of last year was 0.55043093. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=1146.593/2267.127
=0.50574714

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=1262.271/2019.944
=0.62490396

Haemonetics's asset turnover of this year was 0.50574714. Haemonetics's asset turnover of last year was 0.62490396. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+0+1+1+1+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Haemonetics has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
Haemonetics (STU:HAZ) has a Piotroski F-Score of 6 as of Jul. 01, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Haemonetics and its competitors. This is near median its historical median of 6.00. Over the past decade, Haemonetics' Piotroski F-Score has ranged from 5.00 to 8.00. According to the industry distribution chart, Haemonetics ranks #152 out of 806 companies in the Medical Devices & Instruments industry, placing it in the top 18.9%.
Is Haemonetics' Piotroski F-Score too high?
Haemonetics' current Piotroski F-Score of 6 is near median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 8.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Haemonetics' value of 6 is 20% above this industry median. Based on the distribution chart, Haemonetics ranks #152 out of 806 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Haemonetics has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Haemonetics' Piotroski F-Score compare to ITGR and IRTC?
According to the Medical Devices & Instruments industry distribution chart, Haemonetics ranks #152 out of 806 companies for Piotroski F-Score. This places Haemonetics in the top 19% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Haemonetics' value of 6 is 20% above this benchmark. Historically, Haemonetics' own Piotroski F-Score has ranged from 5.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Haemonetics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 806 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haemonetics's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Haemonetics and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haemonetics's current Piotroski F-Score is 6, which is near median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haemonetics stock overvalued right now?
Haemonetics (STU:HAZ) has a current Piotroski F-Score of 6. The stock's GF Value™ is €74.16, compared to a current price of €65.50 — trading 11.7% below its estimated fair value. The current Piotroski F-Score is 6, which is near median its 10-year median of 6.00 and 20% above the Medical Devices & Instruments industry median of 5.00. Haemonetics' overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Haemonetics (STU:HAZ), the current Piotroski F-Score is 6 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Haemonetics (STU:HAZ) Overvalued in 2026?

Based on GuruFocus' analysis, Haemonetics stock appears to be undervalued. The current stock price of €65.50 is trading 11.7% below its estimated GF Value™ of €74.16.

Key valuation signals for STU:HAZ:

  • Piotroski F-Score: 6 (near median its 10-year median of 6.00)
  • GF Value™: €74.16 vs. price of €65.50 (11.7% below fair value)
  • GF Score™: 25/100 with 4 warning signs
  • Industry Position: 20% above the Medical Devices & Instruments median (#152 of 806)

No single metric tells the full story. See the STU:HAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Haemonetics Business Description

Other Exchanges HAE:USA
Address 125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
25GF Score

Get the complete analysis for STU:HAZ

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€65.50
Price
€74.16
GF Value